Clinical trials: Diabetic Macular Oedema
Diabetic Macular Edema (DME)
A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO
A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants with Diabetic Macular Edema - ALTO
- Trial name
- ALTO (NCT07734844)
- Testing
- Tabirafusp tedromer, Aflibercept (2.0 mg)
- Where
- 9 sites in United States
- Volunteers
- 910 people
- Sponsor
- Kodiak Sciences Inc
Macular Edema, Macular Degeneration
Implementation of the Intravitreal Injection Administered by Nurses
Introduction: Intravitreal injections involve medication administration into the eye to treat ocular diseases and protect vision.
- Conditions
- Macular Edema, Macular Degeneration, Diabetic Macular Edema
- Trial name
- NCT06511700
- Testing
- It is a implementation a program incorporating nurses trained in administering intravitreal injections within the functional unit of Ophthalmology following the usual technique
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Corporacion Parc Tauli
Diabetic Retinopathy
Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema
The main objectives of this observational study were to describe outcomes, monitoring and treatment patterns of patients with diabetic macular edema in routine clinical practice who are either treatment naïve patients or…
- Trial name
- APOLLON (NCT02924311)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- France
- Volunteers
- 402 people
- Sponsor
- Bayer
Diabetic Macular Edema
Dextromethorphan for Diabetic Macular Edema
Background: Many people with diabetes have macular edema (swelling) at the back of the eye. Macular edema can cause loss of vision. Studies suggest that inflammation may be involved in the swelling.
- Trial name
- MiDME2 (NCT01441102)
- Testing
- Dextromethorphan hydrobromide
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Eye Institute (NEI)
Diabetic Macular Edema
Safety and Tolerability Study of the Helical Intravitreal Triamcinolone Implant in Diabetic Macular Edema
This Phase 1 study will evaluate the safety, tolerability and duration of effect of a helical intravitreal triamcinolone implant for the treatment of diabetic macular edema over a three-year period.
- Trial name
- STRIDE (NCT00915837)
- Testing
- triamcinolone acetonide
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- SurModics, Inc.
Diabetic Macular Oedema
To Evaluate the Comparative Efficacy of Lucentis (Ranibizumab) 0.5mg Intravitreal Injection in Patients With Diabetic Macular Oedema (DME) With Well Controlled and Poorly Controlled Diabetes Mellitus
To demonstrate the comparative effectiveness of 12 months of Lucentis (ranibizumab) in patients with well controlled compared to those with poorly controlled diabetes using an PRN treatment schedule.
- Trial name
- CONTROL (NCT03495765)
- Testing
- Ranibizumab
- Where
- Australia
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Marsden Eye Specialists
Diabetic Macular Edema
577nm Micropulse Laser Versus 532nm Subthreshold Laser Photocoagulation for Diabetic Macular Edema
This randomized, parallel controlled, clinical-trial aims to evaluate the therapeutic efficacy and safety of 577nm micropulse laser photocoagulation for diabetic macular edema compared with 532 subthreshold laser photocoagulation.
- Trial name
- NCT02406157
- Testing
- 577-MPL, 532-SLP
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Sun Yat-sen University
Non-center Involved Diabetic Macular Edema, Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
Study of INV-102 Ophthalmic Solution in Adults With Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
Phase 2 study to assess the efficacy of topically administered eyedrops of INV-102 during a 12-week dosing period in subjects with non-center involved DME (NCIDME) associated with NPDR [Part 1] and during an 8-week dosing period…
- Conditions
- Non-center Involved Diabetic Macular Edema, Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy, Diabetic Retinopathy, Center-involved Diabetic Macular Edema
- Trial name
- NCT06599684
- Testing
- INV-102
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Invirsa, Inc.
Choroidal Neovascularization, Macular Edema
An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.
The pupose of this study is to evaluate the safety and the efficacy of ranibizumab in rare VEGF driven ocular diseases.
- Conditions
- Choroidal Neovascularization, Macular Edema, Glaucoma, Neovascular, Diabetic Retinopathy
- Trial name
- ECLIPSE (NCT01908816)
- Testing
- ranibizumab
- Where
- 39 sites in France
- Volunteers
- 270 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Retinopathy
Laser Therapy Combined With Intravitreal Aflibercept vs Intravitreal Aflibercept Monotherapy (LADAMO)
This will be a 24 month phase IV, randomised, prospective, multicentre, clinical trial of laser therapy to areas of peripheral retinal ischaemia combined with intravitreal aflibercept versus intravitreal aflibercept monotherapy.
- Trial name
- LADAMO (NCT02432547)
- Testing
- Aflibercept, Targeted laser therapy
- Where
- 2 sites in Australia
- Volunteers
- 48 people
- Sponsor
- University of Sydney
Diabetic Macular Edema, Diabetic Retinopathy
A Study Intravitreal THN391 in Diabetic Macular Oedema Secondary to Non-Proliferative Diabetic Retinopathy.
THN391-OPT-101 is a study assessing safety and preliminary efficacy of THN391 in patients with diabetic macular edema (DME) given as monotherapy.
- Trial name
- NCT06701721
- Testing
- THN391
- Where
- 10 sites in Australia, Georgia
- Volunteers
- 21 people
- Sponsor
- Therini Bio Pty Ltd
Diabetic Macular Edema
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept in participants with treatment-naïve DME.
- Trial name
- GLEAM (NCT04611152)
- Testing
- KSI-301, Aflibercept
- Where
- 75 sites in United States, Germany and 6 more
- Volunteers
- 460 people
- Sponsor
- Kodiak Sciences Inc
Diabetic Macular Edema
Topical Ocular Mecamylamine in Diabetic Macular Edema (DME)
This is an open-label study evaluating the safety and tolerability of topical ocular mecamylamine given twice a day in patients with diabetic macular edema (DME). Patients will be treated for 12 weeks.
- Trial name
- NCT00536692
- Testing
- mecamylamine
- Where
- 3 sites in United States
- Sponsor
- CoMentis
Macular Edema Due to Type 2 Diabetes Mellitus
Efficacy Analysis of Anti-VEGF Drugs Combined With Micropulse Laser in the Treatment of Diabetic Macular Edema
The goal of this clinical trial is to clarify the efficacy of anti-vascular endothelial growth factor (anti-VEGF) drugs combined with subthreshold micropulse laser (SML) therapy on retinal function and anatomical recovery in…
- Trial name
- VEGF (NCT05759884)
- Testing
- Anti-VEGF, subthreshold micropulse laser
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Diabetic Macular Edema
Gene Therapy for Diabetic Macular Edema
FT-003 is a gene therapy product developed for the treatment of central involvement diabetic macular edema (CI-DME). Diabetic retinopathy is one of the most common microvascular complications of diabetes mellitus, and diabetic…
- Trial name
- NCT05916391
- Testing
- FT-003
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Frontera Therapeutics
Diabetic Macular Edema
Compare Safety/Efficacy of Labeled vs Wait-Extend Regimen of Lucentis in Turkish Patients With VI Due to DME
To explore a more clinical feasible treatment regime with ranibizumab for DME to provide satisfactory treatment effect with a lower number of visits and injections.
- Trial name
- SALUTE-D (NCT02262260)
- Testing
- Labeled regime arm, Wait and Extend regime arm
- Where
- 9 sites in Turkey (Türkiye)
- Volunteers
- 87 people
- Sponsor
- Novartis Pharmaceuticals
Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
The study will evaluate the safety of ophthalmic bevacizumab in subjects diagnosed with a retinal condition that would benefit from treatment with intravitreal injection of bevacizumab, including: exudative age-related macular…
- Conditions
- Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, BRVO - Branch Retinal Vein Occlusion
- Trial name
- NCT04516278
- Testing
- bevacizumab
- Where
- 20 sites in United States
- Volunteers
- 197 people
- Sponsor
- Outlook Therapeutics, Inc.
Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME)
A Phase I Study of GenSci148 Intravitreal Injection for Neovascular Age-related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion
This is a Phase I, multicenter, open-label, dose-escalation study conducted in two parts to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of GenSci148 administered via intravitreal (IVT)…
- Conditions
- Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO)
- Trial name
- GenSci148-101 (NCT07817615)
- Testing
- GenSci148 Injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Diabetic Retinopathy, Diabetes Complications
Study Evaluating Efficacy and Safety of PF-04523655 Versus Laser in Subjects With Diabetic Macular Edema
To evaluate the effectiveness of study drug in improving visual acuity compared to laser treatment in the patients with diabetic macular edema
- Trial name
- DEGAS (NCT00701181)
- Testing
- Laser Treatment, PF-04523655 high, PF-04523655 middle
- Where
- 53 sites in United States, Denmark and 6 more
- Volunteers
- 184 people
- Sponsor
- Quark Pharmaceuticals
Diabetic Macular Edema
Ranibizumab Versus Dexamethasone Implant in Diabetic Macular Edema
Between December 2016 and June 2017 a total of 40 eyes from 40 diabetic retinopathy patients with diabetic macular edema were recruited at the Ophthalmologic Clinic of University "G. d'Annunzio", Chieti-Pescara, Italy.
- Trial name
- LED (NCT03385382)
- Testing
- Dexamethasone intravitreal implant 0.7 mg, Ranibizumab Injection
- Volunteers
- 40 people
- Sponsor
- G. d'Annunzio University